{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in \nTreatment-na\u00efve Subjects with Advanced or Metastatic PD-L1 High (TPS \u226550%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations \n(TROPION-Lung08)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-randomized-open-label-phase-3-trial-of-dato-dxd-plus-pembrolizumab-vs-pembrolizumab-alone-in-treatment-naive-subjects-with-advanced-or-metastatic-pd-l1-high-tps-%e2%89%a550-non-small-cell-lung-2\/#breadcrumbitem"}]}